Evidence map›Paper›PMID 39359619›Full record

ArticleFrontiers in human neuroscience2024

Neuromuscular impairments of cerebral palsy: contributions to gait abnormalities and implications for treatment.

Kylie Clewes, Claire Hammond, Yiwen Dong, Mary Meyer, Evan Lowe, Jessica Rose

Abstract read
In one paragraph

Article in Frontiers in human neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Lower Extremity Musculoskeletal Complications of Spastic Cerebral Palsy.Journal of orthopaedics and sports medicine · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kylie ClewesMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.
Claire HammondMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.
Yiwen DongMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.
Mary MeyerMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.
Evan LoweMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.
Jessica RoseMotion and Gait Analysis Lab, Lucile Packard Children's Hospital, Stanford Medicine Children's Health, Palo Alto, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of neuromuscular impairments in cerebral palsy (CP) is essential to providing effective treatment. However, clinical recognition of neuromuscular impairments in CP and their contribution to gait abnormalities is limited, resulting in suboptimal treatment outcomes. While CP is the most common childhood movement disorder, clinical evaluations often do not accurately identify and delineate the primary neuromuscular and secondary musculoskeletal impairments or their specific impact on mobility. Here we discuss the primary neuromuscular impairments of CP that arise from early brain injury and the progressive secondary musculoskeletal impairments, with a focus on spastic CP, the most common form of CP. Spastic CP is characterized by four primary interrelated neuromuscular impairments: 1. muscle weakness, 2. short muscle-tendon units due to slow muscle growth relative to skeletal growth, 3. muscle spasticity characterized by increased sensitivity to stretch, and 4. impaired selective motor control including flexor and extensor muscle synergies. Specific gait events are affected by the four primary neuromuscular impairments of spastic CP and their delineation can improve evaluation to guide targeted treatment, prevent deformities and improve mobility. Emerging information on neural correlates of neuromuscular impairments in CP provides the clinician with a more complete context with which to evaluate and develop effective treatment plans. Specifically, addressing the primary neuromuscular impairments and reducing secondary musculoskeletal impairments are important treatment goals. This perspective on neuromuscular mechanisms underlying gait abnormalities in spastic CP aims to inform clinical evaluation of CP, focus treatment more strategically, and guide research priorities to provide targeted treatments for CP.

Indexed as

brain injurycerebral palsygait abnormalitiesmusculoskeletal impairmentsneuromuscular impairments

Identifiers

PMID39359619
PMCPMC11445151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.